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Summary 
 
It is hoped that the use of gene transfer technology to treat both monogenetic and 
acquired diseases may soon become a common therapy option in medicine.  For gene therapy 
to achieve this objective, any gene delivery method will have to meet several criteria, including 
ease of manufacturing, efficient gene transfer to target tissue, long-term gene expression to 
alleviate the disease, and most importantly safety in patients.  Viral vectors are an attractive 
choice for use in gene therapy protocols due to their relative efficiency in gene delivery.  Since 
there is inherent risk in using viruses, investigators in the gene therapy community have 
devoted extensive efforts toward reengineering viral vectors for enhance safety.  Here we 
review the approaches and technologies that are being evaluated for the use of recombinant 
vectors based upon adeno-associated virus (AAV) in the treatment of variety of human 
diseases.  AAV is currently the only known human DNA virus that is non-pathogenic and AAV-
based vectors are classified as Risk Group 1 agents for all laboratory and animal studies carried 
out in the US.  Although its apparent safety in natural infection and animals appears well 
documented, we examine the accumulated knowledge on the biology and vectorology of AAV, 
lessons learned from gene therapy clinical trials, and how this information is impacting current 
vector design and manufacturing with an overall emphasis on biosafety. 
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Introduction 
 
Gene transfer technology has gone through multiple stages in the last 45 years.  The 
initial concepts were conceived in the late 1960s with the first clinical trial occurring in the early 
1970s (1).  While the idea of “gene surgery” was optimistic in the beginning, public concern 
heightened over the next three decades due to clinical trials that were hampered by inefficient 
technologies and safety concerns associated with viral vectors (2-4).  Recent advances in 
vector technologies have enabled investigators to increase the safety and efficacy of gene 
delivery and these improvements have led to renewed interest in gene therapy, successful 
clinical trials, and the first approved gene delivery product in Europe (5).  One of the most 
commonly used vectors is based on adeno-associated virus (AAV).  Recombinant AAV (rAAV) 
vectors have several advantages, including long-term gene expression, relatively low 
immunogenicity, minimal toxicity, and no association of AAV with any disease (6).  In addition, 
rAAV vectors have a demonstrated safety record in research laboratories, preclinical animal 
studies, and many early-stage clinical trials.  While this biosafety profile is encouraging, there 
are still risks that investigators and patients should consider.  
 
AAV Biology 
 
AAV is a member of the parvovirus family and has been classified as a dependovirus 
due to the requirement for co-infection with helper viruses such as Adenovirus (Ad) or Herpes 
Simplex virus (HSV) for productive infection (7).  AAV is one of the smallest known viruses and 
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contains a linear, single-stranded DNA genome of about 4.7 kilobases (Figure 1).  The wild-type 
(wt) AAV genome is made up of three genes flanked by two 145-bp inverted terminal repeats 
(ITRs) that form T-shaped hairpin structures.  The ITRs function in viral genome packaging, 
serve as the origin of replication, and as integration elements (8,9).  The first gene, rep, 
encodes four replication proteins.  The larger replication proteins, Rep 78 and 68, are splice 
variants originating from the p5 promoter.  Rep 68/78 play a role in many aspects of the lifecycle 
of AAV; the large Rep proteins are necessary for transcription, nicking and unwinding of the 
ITRs, viral DNA replication, and site-specific integration into human chromosome 19 (10).  The 
small replication proteins, Rep 40 and 52, have been shown to be important for packaging of the 
viral DNA into viral capsid within the nucleolus of producer cells.  The second gene, cap, 
encodes three capsid proteins and viral assembly factor. The capsid proteins are produced from 
the same open reading frame (ORF) but utilize different translational start sites.  The assembly-
activating protein (AAP) is encoded from a nested, alternative ORF and targets the capsid to the 
nucleolus for virion assembly.   
 
AAV particles are non-enveloped, icosahedral structures of approximately 25 nm in 
diameter and have a triangulation number of 1.  The virion is made up of a total of 60 of the 
three capsid proteins Vp1, Vp2 and Vp3 at a 1:1:10 ratio, respectively.  All three capsids share 
the common VP3 region, while VP1 and VP2 have additional amino-terminal structures.  The 
exposed surface residues in the VP3 region are used for binding to cellular matrices and 
recognition of cellular receptors defining the tropism of AAV.  The VP1 capsid subunit is 
required for infectivity and contains a phospholipase domain which is thought to function in 
endosomal escape (11,12).  It has been shown that AAV particles that lack VP2 are fully 
functional, suggesting that this protein is dispensable for infectivity (13).  The capsid structures 
for a number of the different AAV serotypes have been solved, including AAV1, AAV2, AAV3b, 
AAV4, AAV5, AAV6, AAV7, AAV8, and AAV9 (14-25).  These studies have revealed that the 
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different serotypes share a very common structure.  These include depressions at the 2-fold 
axis and around both the 3-fold axis and the 5-fold axis, variable loops at the 3-fold axes 
protrusions, and a pore at the 5-fold axis of symmetry.  The loops and base at the 3-fold axis 
are thought to be critical for binding to target cells through glycan residues in the extracellular 
matrix (26,27), while the 5-fold channel is involved in viral genome packaging and possibly 
genome release (28).  The 2-fold axis of symmetry has been implicated in uncoating (29,30), 
but the role of the other capsid regions in viral disassembly is not completely understood.    
 
The AAV virus infectious pathway can take two forms, latent and productive, depending 
on whether the cells are co-infected with a helper virus such as Ad.  In both pathways the 
transduction of target cells begins by AAV first binding to cell surface glycans on target cells 
such as heparan sulfate for AAV2 and AAV6, sialic acid for AAV1, AAV4, and AAV5, or 
galactose for AAV9 (Figure 2) (31,32,32-35).  After attachment the virus utilizes coreceptors for 
internalization.  Integrins (such as αVβ5 and αVβ1), fibroblast growth factor (36), platelet-
derived growth factor receptor (37), and the laminin receptor (38) have been shown to function 
in AAV receptor mediated endocytosis in a clathrin-dynamin-mediated manner.  Following 
cellular uptake the virus is thought to undergo conformational changes during acidification of the 
endosome, resulting in exposure of a phospholipase region in the VP1 subunit and subsequent 
endosomal escape (12).  Basic regions in VP1 and VP2 have been shown to act as nuclear 
localization signals (39-42).  The microtubule network has been shown to be important for the 
virus to intracellular transport to the perinuclear region (43).  AAV is thought to translocate into 
the nucleus through active import (44).  Once in the nucleus, the viral genome is released from 
the capsid and must undergo synthesis of the complementary strand that is initiated from the 3’ 
ITR.  AAV can undergo productive infection in the presence of a helper virus and the viral 
genome can integrate in the host chromosome in a Rep-dependent fashion (45).  Following 
transcription and translation, nascent viral particles are formed in the nucleus of producer cells.  
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A newly identified AAV viral protein, AAP, has been shown to promote the shuttling of capsid 
proteins to the nucleolus for particle assembly (46,47).  The single-stranded AAV genomes are 
packaged into capsids presumably by spooling the DNA through the 5-fold pore; the 3’ end first 
through the action of Rep78/52 (28,48).  Fully assembled particles are then released from the 
cells during helper virus mediated cellular lysis or potentially through exocytosis (49). 
 
AAV has traditionally been thought of as a safer platform for a viral vector due to the 
natural requirement of a helper virus for productive infection.  Ad, HSV, Vaccinia virus, and 
Human Papillomavirus have been shown to be able to rescue AAV infection (50-53).  It has 
been shown that genotoxic agents that induce cell stress, such as hydroxyurea or UV light can 
also promote AAV replication in some cell lines (54-56).  In addition, AAV has also been shown 
to productively infect cultures of differentiating keratinocytes (57).  Therefore, it is possible that 
AAV can autonomously replicate under some conditions.  Interestingly, AAV has been shown to 
inhibit the replication of a number of viruses (52,58-61), suggesting that in some cases AAV 
infection may be protective against many of the same viruses it utilizes for helper functions. 
 
While the functions of the necessary components for AAV replication have been 
investigated for a variety of helper viruses, the function of a subset of the Ad genes have been 
the most extensively studied.  Four Ad proteins have been shown to be necessary to provide 
the Ad helper functions; these are the early region E1A, E1B, E4orf6, and E2A. In addition, the 
transcription of the Ad virus-associated (VA) RNAs is essential.  The E1A protein is an 
oncogene that has pleiotropic effects on cellular transcription and growth.  It also 
transcriptionally activates the Ad genes and AAV p5 promoter (62).  The E4orf6 and E1B 
proteins interact as a heterodimer and promote viral gene expression by aiding in the transport 
of AAV mRNA to the cytoplasm as well as arresting the cell cycle in G2 or S phase (63-65).  
E4orf6 has also been shown to enhance the conversion of the ssDNA viral genomes into the 
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dsDNA form (66).  E2A is a ssDNA binding protein that aids in activating transcription from AAV 
promoters and may be involved in AAV DNA replication (67,68).  The small, non-coding Ad VA 
RNAs are highly synthesized and enhance the translation of AAV capsid mRNAs by increasing 
the steady-state levels of the transcripts, improving the translation of the proteins, and inhibiting 
the serine-threonine kinase protein kinase R -induced inhibition of capsid subunits (69,70). 
 
Importantly, AAV has not been reported to cause any disease.  AAV was originally 
revealed in electron microscopic studies of preparations of human and simian adenovirus (71).  
This early work showed that the particles were in fact not adenovirus subunits, but a 
contaminating virus that required a helper virus for replication.  Due to the association of AAV 
with adenovirus, early assumptions pointed to a possible participation of AAV in the disease 
response to acute adenovirus infection. However, epidemiology studies in the late 1960s 
established that both children and adults infected with AAV showed no signs of disease and that 
AAV did not appear to alter the clinical expression of acute adenovirus infection (72-76).  
Furthermore, serological surveillance collected from a variety of sources has shown that up to 
80% of the human population has been infected with the AAV2 serotype and there has been no 
correlation with any disease (77-81). 
 
The integration profile of AAV is also advantageous.  AAV can establish a latent infection 
by integrating into a 4-kb unique site on human chromosome 19 that is mediated in part by the 
ITRs and Rep68/Rep78 (82-85).  This locus, known as the AAVS1 site, exists in an open 
chromatin conformation and contains an insulator element (86).  The AAVS1 site is located in 
the MBS85 gene, so genetic mis-regulation has been a concern (87).  Further work by the 
Linden laboratory has determined that there were no discernable gene expression differences 
due to this rearrangement, despite the partial duplication of the MBS85 gene (88).  Since 
integration into the AAVS1 site has not been shown to cause tumor formation or to be 
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cytopathic in cells, it has been deemed a “safe site” for integration.  Due to this lack of toxicity, 
others have targeted this site for integration using a number of vectors in an effort to avoid 
insertional mutagenesis associated with random integration (89-91). However, most of the work 
associated with integration into the AAVS1 site, has been conducted in vitro.  Further studies in 
animals will be required to definitively establish the AAVS1 region as a safe-site for integration. 
 
 It has also been shown that wild-type AAV exists as extra-chromosomal concatemers in 
normal human tissue or integrates randomly into open chromatin (92,93).  Rep expression in 
target cells is usually dependent on acute co-infection of the cells with a helper virus such as Ad 
or HSV.  In the absence of Rep expression, the viral DNA cannot integrate into the AAVS1 site, 
so the transgene usually exists in episomal form (Figure 2).  In tissues that are largely 
composed of non-dividing cells such as muscle or the brain, the viral DNA can remain for 
lifespan of the infected animal or individual.  In rapidly dividing cells, the viral episomes are 
quickly diluted from the population.  From a safety standpoint, the low level of integration implies 
a relatively slim chance of tumorigenesis, due to the small probability of disruption of tumor 
suppressor genes or the activation of oncogenes.  This reasoning matches the lack of 
epidemiological evidence for exposure to AAV as a risk factor for cancer.  A study that 
investigated the infection of rhesus macaques with wild-type AAV by intravenous, intramuscular, 
and intranasal routes showed no evidence of increased risk of tumorigenesis in the animals 
(94).  Since AAV integrates preferentially in mammalian cells that have faulty DNA repair and 
that are lacking expression of the tumor suppressor p53, it suggests that cancerous cells are 
more prone to AAV integration at the AAVS1 site (95).  It has also been demonstrated that Rep 
can interact with p53 (96).  Therefore, it is possible that in normal, non-cancerous cells that are 
infected with wild-type AAV without helper virus, the little Rep68/78 that is expressed is bound 
by p53.  This scenario could lead to inhibition of AAVS1 integration, and subsequent 
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concatemerization or non-specific integration of AAV genomes observed in normal human 
tissue.  
 
Parvoviruses are known to cause cell cycle arrest and cell death.  For AAV, this is 
largely due to the expression of Rep.  The expression of Rep78 in cells has shown to cause an 
S phase arrest of cells (97).  Further studies showed that Rep induces a DNA damage response 
(DDR) that is caused by two separate activities (98).  First, Rep78/68 activity is responsible for 
nicking of the host cell chromatin at purported Rep-binding sites; an estimated 2×105 such 
recognition sequences are thought to exist in the human genome (45).  Secondly, the zinc-
finger domain of Rep functions to bind and inhibit the activity of Cdc25A.  This action interferes 
with the Cdc25A-dependent activation of Cdk1 and Cdk2, which contributes to the lack of cell 
cycle progression.  Rep has also shown to be cytotoxic through the induction of apoptosis.  
Rep78 is capable of activating the apoptosis pathway in a caspase-3-dependent manner (99).  
Further studies have also demonstrated that caspase-independent pathways can be triggered 
by AAV (100), which appear to be due to Rep78 expression.  In addition to the actions of 
Rep78, genomic elements of the virus have similarly shown the capacity to stimulate a DNA 
damage response.  The ITRs have been suggested to mimic stalled replication forks and that 
this structure can mediate the death of p53-deficient cells (101,102).  However, later work failed 
to show a DDR invoked by rAAV vectors and instead pointed to cis-acting AAV DNA 
sequences, such as p5 promoter (103) or DNA-dependent protein kinase catalytic subunit 
(DNA-PKcs) -mediated DDR caused by viral replication itself (104). 
 
Vectorology of rAAV 
 
AAV has become one of the most common viral vector platforms in gene delivery due to 
a number of desirable features.  These include their simple design, ease of manufacturing, wide 
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range of infectivity, long-term expression of delivered genes, and excellent safety record in 
clinical trials.  Furthermore, reengineering of the viral genome and capsid has given rise to 
recombinant AAV (rAAV) vectors that have enhanced tropism, expression, and safety.  While 
numerous clinical trials have been conducted using rAAV vectors with no serious adverse 
events, it has become clear that there are some outstanding issues that have yet to be tackled 
for rAAV to be successful for various indications. 
 
In conventional rAAV vectors, the rep and cap genes are removed and are replaced by 
an exogenous promoter, gene of interest, and polyadenylation signal.  The ITRs which flank the 
transgene are the only cis-acting elements that are retained in the vector genome (Figure 1).  
The AAV rep and cap genes are provided in trans during vector production.  This separation is 
necessary due to the 4.7 kb size constrain of the rAAV vector and it also serves to limit the 
production of wild-type AAV particles.  To avoid the possible contamination of rAAV 
preparations with Ad or HSV helper viruses, most production systems utilize a two or three 
plasmid transfection method (105,106).  Recently, the NIH has classified all serotypes of rAAV 
vectors made in the absence of helper viruses as Risk Group 1 agents, if the transgene does 
not encode for a toxic or potentially tumorigenic gene.  A practical application of this guideline is 
that many rAAV vectors can be used in most laboratories and animal facilities without additional 
biosafety concerns.  Therefore, it is important to consider the source of the vector and how it 
was generated and purified to ensure that the NIH classification in applicable.  In addition, the 
manufacturing of rAAV vectors should be performed BSL2 facilities for production platforms that 
utilize HEK293 cells, HeLa cells, Ad, or HSV (Risk Group 2). 
Early in the development of AAV as a recombinant vector system most laboratories 
utilized the AAV2 capsid and ITRs.  As other serotypes were discovered it was noted that some 
had distinct bio-distribution profiles (107-110).  To develop these novel serotypes as vectors, 
most vector particles are constructed to contain the ITR from AAV2 and the capsid from the 
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different serotype, since transgenes containing the AAV2 ITRs can be packaged into capsids 
from almost any serotype (107,111-113).  By transencapsidating reporter genes into various 
capsids it was observed that many had important clinical applications (Figure 3).  For example, 
rAAV5 vectors have enhanced transduction of neurons (114), rAAV8 vectors display an 
increased tropism for the liver, while rAAV7 and rAAV9 vectors allow for a more systematic and 
enhanced expression of transgenes (107,113). 
Second-strand synthesis is a major rate-limiting step for the transduction of cells with 
rAAV vectors and this is especially evident in cells that are post-mitotic with limited DNA 
replication machinery.  Self-complementary (sc) vectors were developed to bypass this step 
(115,116).  During production, the sc-transgene plasmid contains one normal ITR and another 
that has a deletion of the terminal resolution site.  This mutation prevents the mutant ITR from 
being nicked by Rep during replication in producer cells and results in double-stranded form of 
the transgene being incorporated into nascent particles.  It has been well demonstrated that 
recombinant scAAV vectors exhibit an enhanced expression in vitro and in vivo animal studies 
(117,118).  One downside of this strategy is that the packaging capacity of recombinant scAAV 
vectors is approximately 2.5 kb.  This further limits many of the genes that can be packaged into 
AAV-based vectors and often requires smaller promoters and poly A signals to retain 
expression.  Another challenge with these vectors is that they may be more easily recognized 
by innate intracellular pathways.  Several studies have indicated that Toll-like receptor 9 is 
activated by scAAV vectors (119,120), although vectors depleted of CpG sequences may avoid 
this activation (121). 
Another option that is being explored to overcome the natural packaging size of AAV is 
to produce vectors that allow the production of larger genetic material during concatemerization 
in target cells (122,123).  This process is call trans-splicing and relies on the propensity for the 
ITRs from two separate transgenes to recombine and the RNA message to be correctly spliced.  
This technique has shown the ability to deliver genes up to 10-kb in size, which drastically 
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improves the applications that could use rAAV (124).  The drawback to this method is the 
dependence on multiple vectors transducing the same cell to accumulate sufficient mRNA and 
produce a therapeutic protein.  Target cells are usually transduced by one particle or less in 
most clinical applications.  Therefore, it is presently unclear what doses might be required for 
efficient delivery of donor and acceptor vectors and whether these doses would be acceptable 
for patient safety. 
 
Risks Associated with rAAV Gene Therapy 
 
Risk of Dissemination 
A biosafety concern for rAAV is the risk of secondary spread of the vector transgene by 
shedding, mobilization, or germ line transmission.  Shedding is the dissemination of the vector 
from treated animals or patients in urine, feces, tears, or other bodily fluids (125).  For rAAV 
vectors, shedding is primarily due to the release of vectors that did not infect target cells at the 
time of administration, but were cleared or released from the patient or animal.  Most studies of 
rAAV vector shedding have been performed in the context of clinical trials (125-131) and have 
concluded that the risk of shedding is low and dependent on the route of administration.  
Preclinical evaluations of rAAV shedding have also shown that shedding is transient and that 
exposure to the vector is limited to relatively low numbers of particles (132,133).  In addition, a 
wealth of preclinical and clinical data has shown that successful transduction requires relatively 
larger quantities of vector than the amount of the vector that is shed, and that the vector must 
be administered through systemic or localized delivery.  Despite this low safety hazard, it is 
advisable for laboratory, vivarium, and hospital workers who may come in contact with bodily 
secretions or excreta to utilize proper protective equipment such as surgical masks, lab coats, 
protective eyewear, and disposable gloves (134). 
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For rAAV vectors, mobilization of the vector differs from fundamentally from shedding.  
Mobilization of rAAV vectors requires that target cells be infected with the vector in order to 
deposit the vector transgene.  Vector mobilization also necessitates that the same cells are also 
infected with a suitable helper virus and wild-type AAV in order to mobilize copies of the 
transgene out of the cell or host and into nascent vector particles.  Nearly all rAAV vectors 
utilize the ITR structures from AAV2.  Due to the prevalence of AAV2 in the human population 
there is the potential for cells transduced with a rAAV vector to also be infected with wild-type 
AAV2 and a helper virus.  This could allow the rAAV vector genome to be replicated and 
mobilized into new cells or individuals (135).  Data from a number of laboratories has shown 
that this is theoretically possible (82,135,136).  To overcome this risk, it will be important to 
develop rAAV vector transgenes with novel ITRs that cannot be recognized by wild-type Rep or 
packaged into the capsids of wild-type virus. 
A serious concern for vertical and horizontal transmission of rAAV vectors is through 
seminal fluid.  While the gene transfer risk is low for the sexual partners of the male, the 
possibility of germ line transmission increases the chance of genetic transmission to offspring of 
rAAV recipients.  This is theoretically possible, since it has been shown that rAAV vectors can 
be used to generate transgenic animals by the transduction of male germ line stem cells (GSCs) 
with rAAV (137,138).  Even in these studies that bypassed the natural barriers and replaced the 
endogenous GSCs, the rates of transgenic animals were relatively low, suggesting the 
likelihood of vertical transmission is minimal.  In a Phase I open label dose-escalation safety trial 
evaluating the safety of rAAV-FIX administered via injection of the hepatic artery vector 
transgenes were found in the semen of a 63-year-old research participant, raising the concern 
for transmission of genetic material in humans (139).  While semen samples tested positive for 
AAV-FIX transgenes until week 12 post-administration, no copies of the vector genomes were 
observed in the patient’s motile sperm.  Earlier data from this same group also showed that 
intramuscular injection of mice and intrahepatic injection of rats with rAAV-FIX showed a dose-
14 
 
dependent level of vector transgene in the animal’s gonads (140).  The authors demonstrated 
that intramuscular injection of rAAV-FIX into rabbits revealed that the vector could be localized 
to the basement membrane and vessel walls of the testicular tissue, but was not detected in 
semen samples.  Additionally, semen samples from injected dogs did not show the presence of 
vector transgenes.  In work that analyzed the bio-distribution of rAAV in nonhuman primates 
vector genomes were undetectable in male germ line cells. A study of the safety of rAAV in 
rhesus macaques found that the gonads were consistently negative for transgene sequences 
following intramuscular injection (141) and the presence of vector genomes was not detected in 
the gonads of baboons following intramuscular administration of rAAV-AAT (142). However, 
other work has shown that vector genomes can be found in almost all gonads of macaques 
following intramuscular injection and regional intravenous administration of rAAV1 and rAAV8 
vectors (143).  In addition, evaluations of AAV1-AAT in mice and rabbits found vector in rabbit 
semen.  Risk is still considered low since rAAV apparently cannot infect sperm cells and 
infectious virus cannot be recovered from semen (140,144,145).  In addition, rAAV bio-
distribution to the semen appears to clear by 12 weeks for serotypes 2, 5, 6, and 8 (132,145), so 
any risk would be transient and simply addressed by barrier contraception.   
 
Risks Associated with rAAV Production 
Contamination with helper virus 
 Early rAAV production strategies relied on the use of adenoviral vectors to provide the 
helper virus functions required for AAV replication.  These platforms depend on the heat stability 
of AAV and temperature sensitivity of adenovirus.  By heating the partially purified viruses at 
56°C for 30 minutes, the majority of adenovirus is inactivated, while the AAV vector is stable.  
Intact adenovirus is then further purified from the AAV vector by ultracentrifugation or 
chromatography, although adenoviral proteins are often still present and difficult to remove.  
Adenovirus is not required in current production platforms, since the genes required for helper 
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virus functions have been identified and can be provided in trans (105).  For systems that still 
employ adenovirus or herpes virus for helper functions, it is imperative to demonstrate that the 
final preparations of rAAV vector are devoid of contaminants from the helper viruses. 
 
Risk related to the creation of replication-competent AAV by recombination 
Although wild-type AAV has not been associated with any disease, it is considered an 
unwanted impurity in vector preparations.  The possibility exists that the presence of wild-type 
AAV could heighten non-specific integration, increase the risk of vector mobilization, or cause 
toxicity in target cells due the presence of Rep (146).  Although most production methods utilize 
separate plasmids for the rep-cap AAV helper and the vector transgene, it appears that 
recombination between these plasmids can give rise to replication competent AAV (RC-AAV) 
particles that resemble the wild-type virus (147,148).  The RC-AAV particles can contribute to 
10% of the total vector preparation if not properly controlled (148,149).  Due to this propensity 
for recombination, several strategies have been employed to reduce the chance of RC-AAV 
contamination.  One approach is to place the rep and cap genes in opposite orientations, on 
separate plasmids, or by inserting introns within the rep and cap genes.  This method has been 
shown to decrease the presence of RC-AAV to undetectable levels during large-scale 
production (149-151).  Another innovative method was developed by the laboratory of Weidong 
Xiao; this system uses vaccinia virus to deliver and restrict the cap and rep genes to the 
cytoplasm, thereby avoiding the potential for recombination and RC-AAV production (152).  It is 
also important to develop validated assays for the detection of RC-AAV particles, especially if 
the vector being produced is intended for preclinical or clinical use.  These assays generally 
employ three or more rounds of infection cycles on a permissive cell line in the presence of 
adenovirus followed by detection by end-point PCR and agarose gel electrophoresis. 
 
Risk Related to Integration 
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Serious health risks have been seen in clinical trials with retroviral vectors due to 
insertional mutagenesis and the subsequent induction of oncogenesis (4,153,154).  While rAAV 
vectors display a much lower likelihood of integration into the target cell genome, the hazard of 
insertional mutagenesis is worrying and numerous investigators have explored this risk.  Unlike 
wild-type AAV, most rAAV vectors lack the rep gene and are therefore deficient for targeted 
integration into the host chromosome at the AAVS1 site.  Instead rAAV vectors predominantly 
circularize to form episomal structures.  While this limits the effectiveness of AAV-based vectors 
to non-dividing cells, concatameric DNA assemblies of the transgene are generally considered 
to be safe.  Most studies that have assessed the non-specific integration capability of rAAV 
vectors have concluded that this background integration is relatively low (155-157).  In contrast, 
several reports have suggested that the risk of insertional mutagenesis is potentially much 
higher, especially in the liver (158-162).  During a study evaluating the treatment of neonatal 
mucopolysaccharidosis type VII (MPS VII) mice with a rAAV2 carrying a -glucuronidase gene 
driven by the chicken -actin promoter, a significant incidence of tumorigenesis was observed in 
the animals (160).  In agreement with this troubling finding, subsequent work found that rAAV 
integration events were potentially deleterious and tumorigenic (158,159,163,164).  The findings 
included evidence for integration hot-spots near regulatory sequences, observations that rAAV 
vector integration sites were associated with a substantial percentage of deletions, and signs 
that integration predominantly occurred in active genes or fragile sites in the chromosomes 
(158,163,164).  Recent work (161,162), and in the 2007 study by Donsante et al. (159), proviral 
insertions were found in rAAV transformed cells that mapped to a locus on chromosome 12 that 
contains small nucleolar RNAs and microRNAs that could affect cell cycle regulation.  Two of 
the integration sites were found within the mir-341 microRNA transcript, suggesting that mir-341 
may be a preferential target for rAAV vector integration.  In more recent work, significantly 
higher rates of tumor formation in hepatocellular carcinoma-prone mice following administration 
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with scAAV vectors has been observed, with integration patterns that likely led to read-through 
transcription, enhancer activation, and tumor suppressor deregulation (162).  However, in these 
reports the authors tended to use tumor-prone or neonatal mouse models to investigate the 
likelihood of AAV-mediated tumorigenesis.  Furthermore, the vector transgenes often 
incorporated bacterial origins of replication, evaluated a limited number of integration events, 
and utilized vector preparations that were not of clinical-grade quality.   
In a recent high-throughput analysis that investigated the potential for insertional 
mutagenesis, a high dose of cGMP-grade rAAV2 human Factor IX vector was administered in 
an adult mouse model and linker-mediated polymerase chain reaction (LM-PCR) and 454 pyro 
sequencing was performed from tissue approximately 18 months post-injection (165).  Although 
numerous integration events were identified, no evidence for increased genotoxicity was seen. 
This data is in agreement with investigations in non-human primates and clinical trial patients 
that utilized linear amplification-mediated (LAM)-PCR and deep sequencing and found random 
and low frequency of integration (10-5 to 10-4) without tumorigenesis (157,166,167).  These 
findings are supported by studies that have not found any increase of tumorigenesis in rAAV 
treated animals (168-170).  Furthermore, no evidence for insertional mutagenesis has been 
reported for any individual treated with a rAAV vector, suggesting that the risk to patients or 
laboratory workers is low.   
One solution to the risk of non-specific integration is to develop rAAV vectors that can 
exclusively target the AAVS1 site.  This strategy has been explored in a number of studies that 
have suggested incorporating the Rep protein or using hybrid vectors the rAAV vectors may be 
capable of more specific chromosomal targeting (171,172).  However, the problem with 
illegitimate integration by rAAV vectors may be difficult to avoid.  Recent work that used high-
throughput sequencing identified that wild-type AAV integration at the AAVS1 site only accounts 
for about 45% of the total integration events (161).  This suggests that even with strategies that 
use the natural integration pattern of AAV, there might still be considerable off-target integration.  
18 
 
 
Off-target Effects 
Like any drug product, all gene therapy vectors exhibit some degree of off-targeting.  For 
gene delivery, these effects are seen when the gene of interest is expressed in non-intended 
tissues.  Although the use different serotypes has been shown enhanced expression in certain 
tissues, off-targeting remains a serious concern for the treatment of some indications with rAAV 
vectors.  To build upon the unique properties of different capsids, several groups have 
advanced strategies to improve upon the natural occurring serotypes.  These approaches 
included making simple amino acid changes to a serotype, the mixing of capsid genes to create 
vectors pseudotyped with chimeric capsids, random mutagenesis of the cap gene, or 
introducing targeting ligands (26,173).   
While the discovery of novel serotypes and isolates, as well as the capsid engineering 
efforts have vastly increased the set of useful capsids for clinical objectives, the goal of specific 
targeting vectors has yet to be realized.  In complementary work, several approaches have 
been taken to control gene expression in the event of off target transduction.  One scheme is 
the use of inducible or tissue specific promoters.  For example, promoters have been identified 
that help restrict expression to the heart (174) or human rhodopsin kinase gene to specifically 
drive transgene expression in rods and cones of the eye (175).  An alternative means to control 
expression is through incorporating microRNA targeting sequences into the transgene (176).  
This approach has been demonstrated to restrict expression with rAAV5 vectors in pig eyes and 
rAAV9 vectors outside of the CNS (177-179).  Taken together these different approaches offer 
the potential to tightly control transgene expression to specific organs or cell types. 
 
Control of transgene expression  
With the exception of suicide gene delivery in cancer gene therapy (180), the 
administration of recombinant viral vectors is an irreversible process.  So far, in clinical trials, the 
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level of transgene expression cannot be controlled after vector administration, raising the 
question of the long-term safety of continuous unregulated delivery of therapeutic transgene 
products.  Several regulated systems have been successfully used in animal research but so 
far, none of them meets the requirements for clinical applications. 
Promising switches for in vivo regulation of transgene expression are those regulated at 
the transcriptional level such as the tetracycline-inducible (181) and repressible systems (182), 
the rapamycin- (183,184), and mifepristone-inducible systems (185,186), or at the post-
transcriptional level, using a destabilizing domain regulated by trimethoprim fused to the 
therapeutic protein (187) that has been optimized for in vivo applications (188). 
The limitations of these systems include the inducers toxicity (189,190) or off-target 
effects to the patients (191,192), raising of antibiotic resistance (193), and deleterious effects on 
the environment (194). 
Interestingly, the tetracycline-repressible system was shown to drive biologically-active 
GDNF brain levels upon treatment with doxycycline doses which are below those recommended 
for patients undergoing antimicrobial or anti-inflammatory treatments (195-197). 
In contrast, the more clinically-relevant tetracycline-inducible system requires a one 
order of magnitude higher doxycycline dose to induce biological effects (198).  Efforts to reduce 
inducer’s dose (199) or use alternative inducers combined with rationally-designed (200) or 
evolution-selected (201) tetracycline repressors might ultimately lead to a clinically useful 
tetracycline-inducible genetic switch.  
A second important limitation of the tetracycline-inducible/repressible system is the 
immunogenicity of the transactivator, which contains bacterial (tetracycline repressor) and viral 
(a deleted form of the HSV1 VP16 activation domain) components (202).  Indeed, after 
intramuscular delivery via AAV recombinant virus into non-human primates, a rapid loss of 
transgene expression correlating with a cellular immune response has been described (203).  
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Nevertheless, no immune response has been reported so far in immune-privilege sites such as 
retina (204) and brain (205). 
A fact that further complicated the use of the tet system in clinical applications is that a 
large proportion of the human population (60%) has been exposed to herpes simplex virus 
(206). Replacing the viral VP16-derived activator domain by human activation domains, could 
help reducing the immunogenicity of the Tet transactivator (207).  
In addition, most of these systems do not allow expression to reach the same level of 
transgene expression as constitutive promoters especially in the brain in which the 
bioavailability of the inducers is reduced due to the blood-brain barrier (183,188,208). 
 
Risk Management Measures 
 Although wild-type AAV has not been associated with any disease and rAAV vectors 
have shown an excellent safety profile in a large number of animal studies and many clinical 
trials, it is advisable to use good laboratory and clinical practices to avoid any inadvertent 
exposure. The virus is very stable across a wide range of pH and temperatures; work has 
shown that temperatures of greater than 60°C are required for denaturation of the vector capsid 
(209).  AAV-based vectors have also shown to be stable for a month or longer following 
desiccation or lyophilization (210,211).  Therefore, work areas should be disinfected with the 
use of chemical denaturants such as 0.5% sodium hypochlorite, ionic detergents, or alkaline 
solutions (pH > 9.5).  Personal protective equipment should include protective eyewear, 
laboratory coats, and disposable gloves.  If contact with contaminated aerosolized material is 
possible (e.g. soiled animal bedding), then adsorption masks should be worn.  When possible, 
materials that have come in contact with AAV or rAAV vectors should be autoclaved (134).  
While preexisting immunity to AAV limits the ability of the vector to effectively transduce cells in 
vivo, care should be taken to avoid accidental exposure to open cuts or wounds.  Used needles 
containing AAV or rAAV vectors should be disposed of after use to prevent inadvertent needle 
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sticks and possible infection.  In the event of an accidental needle stick the recommendations of 
the Center for Disease Control and Prevention should be followed (212). 
 
Clinical Trials with rAAV 
 
The rapidly increasing use of AAV vectors in diverse fields of fundamental and 
translational research (from 8 articles in 1990 to 374 in 2010 and 469 in 2012 indexed in 
PubMed- key words: “adeno-associated virus” and “vector”) necessitates a thorough evaluation 
of potential risks related to their dissemination into the environment.  Abundant studies using 
rAAV have been conducted in mice, rats, pigs, dogs, horses, non-human primates, and other 
animal models.  However, these preclinical evaluations have not always been predictive of 
administration during clinical trials with AAV-based vectors.  While rAAV vectors have 
advantageous properties for in vivo gene delivery and the vector has been used safely for gene 
delivery in over fifty clinical trials, efficacy has only been reported in a handful of cases.  A 
number of notable clinical trials are summarized below with some important lessons learned 
from each.  A summary of the more striking data illuminating the some important biosafety 
aspects such as shedding, integration of vector DNA, and risk of insertional mutagenesis, as 
well as immune responses is provided in Table 1. 
 
Lung Diseases - Cystic Fibrosis and Alpha-antitrypsin Deficiency 
Cystic Fibrosis (CF) is the most common autosomal recessive genetic disease in the 
Caucasian population, occurring in 1 of every 3000 live births (213).  The disease results from 
mutations in the CF transmembrane conductance regulator (CFTR) gene which leads to mis-
regulation of the ion channel in organs, especially the upper and lower respiratory tract, and 
typically death due to chronic lung infections.  Despite the problems associated with packaging 
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4.4 kb CFTR transgene, preclinical studies using AAV2 to deliver CFTR to the lungs of rabbits 
and nonhuman primates demonstrated long-term expression of CFTR and no safety concerns 
(135,214).  Importantly, experiments that were performed to address the possibility of vector 
shedding, which the European Medicines Agency and International Conference on 
Harmonization has defined as the “dissemination of the virus/vector through secretions and/or 
excreta of the patient” (215).  These evaluations showed that rAAV2 exhibited no appreciable 
shedding or mobilization when co-infected with adenovirus.  The lack of toxicity and vector 
shedding seen in these studies was also observed in patients treated with rAAV2-CFTR.  
Several Phase I clinical trials showed that rAAV could be safely administered at various doses 
and by different routes, which led to Phase II trials that continued this safety profile 
(126,216,217).  While these studies demonstrated that rAAV2-CFTR was safe, the therapy itself 
was limited.  The weakness was likely due to the intrinsic low transduction capacity of AAV2 for 
airway epithelia.  Further studies have shown that AAV5-derived vectors can improve the ability 
to target the lung (218). 
Another monogenetic lung disease is alpha-antitrypsin (AAT) deficiency.  Severe loss of 
the AAT glycoprotein causes destructive diseases of the lung, liver and pancreas and can lead 
to pulmonary emphysema and the need for liver transplantation.  The current standard of care 
for affected individuals is life long treatment with weekly infusions of AAT derived from human 
plasma.  This protein replacement therapy is costly and has some associated risks.  Several 
clinical trials are addressing the ability of AAV-mediated delivery of AAT through intramuscular 
injection (129,219,220).  In a Phase II dose-escalation study led by Terry Flotte a rAAV1 vector 
carrying the human gene was able to achieve peak levels of AAT between 412 and 694nM after 
administration of the highest dose (6×1012 vector genomes/kilogram of body mass (VG/kg)), 
and the concentration of AAT corresponded to vector dose.  Unfortunately, the serum levels of 
AAT were substantially lower than therapeutic concentrations (220).  While these studies 
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confirmed the safety of rAAV vectors even at doses as high as 4.3×1014 VG, they also 
demonstrated the induction of an immune response against AAV that correlated with loss of 
transgene expression.  It will be necessary to enhance the vector or delivery method to 
overcome this hurdle and attain a functional therapy using rAAV. 
 
Neurological Diseases 
rAAV vectors are being developed for the treatment of several diseases of the central 
nervous system (CNS), including Parkinson’s disease (PD) (221), Alzheimer’s (222), 
amyotrophic lateral sclerosis (ALS) (223), Batten's disease (224), epilepsy, and Canavan 
disease.  The brain is generally considered an excellent target organ for therapy with rAAV; 
vectors serotyped with either AAV2 or AAV5 capsids have been shown to effectively transduce 
neurons and the brain is immune-privileged.  The route of administration, however, is usually by 
direct injection into the brain due to inability of most rAAV vectors to cross the blood-brain 
barrier (BBB) and these infusions carry potential risks, such as hemorrhaging or infection.  In 
addition, there is limited spread of rAAV within the brain, which necessitates multiple injection 
sites for the treatment of some indications.  It has been shown recently that self-complementary 
rAAV vectors pseudotyped with the capsid of AAV9 can infect cells in the CNS after intravenous 
injection (225,226).  While rAAV9 vectors can be used to circumvent the BBB, their expression 
must be tightly controlled since rAAV9 vectors can transduce multiple organs, such as the heart, 
liver, and kidneys, increasing risk of off-target transduction. 
The first clinical trial that used rAAV to target the CNS was for the treatment of Canavan 
disease, a childhood form of leukodystrophy caused by mutations in the gene coding the 
enzyme aspartoacylase (ASPA) (227).  This study used a rAAV2-ASPA vector that was 
delivered by intracranial injection into 10 patients, the youngest of which was 3 months old.  The 
safety data collected for this trial showed that administration of rAAV was well tolerated.  The 
24 
 
immune response to the vector and transgene appeared to be low and no serious adverse 
events related to the vector were reported.  A 10-year follow up of the patients showed an 
excellent long-term safety profile and some clear signs of efficacy for the therapy (228).  The 
authors reported no serious adverse events related to the vector itself and evidence that the 
treatment lowered N-acetyl-aspartate levels, slowed brain atrophy, and improved seizure 
frequency.   
This work was followed up by trials that aimed to treat PD, a degenerative disorder of the 
CNS caused by a loss of dopaminergic neurons in the substantia nigra (SN) region of the 
midbrain.  Thanks to the discovery of the important role of dopamine depletion in PD, a 
breakthrough in the pharmacological treatment of PD was made in the 1960s, in the form of the 
oral administration of L-dopa, the precursor to dopamine (229).  Exogenous L-dopa is taken up 
into remaining DA neurons where it is converted into dopamine by aromatic acid decarboxylase 
(AADC).  With the ongoing loss of DA neurons, though, the uptake of extracellular L-dopa 
declines and increasing doses of L-dopa need to be administered leading to important 
fluctuations (e.g. peak-dose dyskinesias).  Interestingly, three different therapeutically 
paradigms were developed.  In the first, it was hypothesized that continuous delivery of L-dopa 
directly to the striatum via gene therapy could be a significant improvement because L-dopa 
would reach only the clinically relevant target area (230).  A rAAV2 vector expressing AADC has 
been injected in PD patients’ putamen in an attempt to reduce and stabilize the L-dopa dose 
necessary to alleviate the symptoms (231).  Patients received bilateral intra-putaminal infusions 
of rAAV2-AADC.  Data based on PET imaging (221) demonstrated stable transgene expression 
over 4 years confirming the preclinical data on the longevity of rAAV-mediated transgene 
expression (232).  This clinical trial further confirmed the safety and tolerability of rAAV 
intracerebral administration.  The clinical data showed dose-dependent improvements but even 
in the high-dose group in which all patients improved in the first 12 months, a slow deterioration 
was observed in subsequent years that is thought to be related to continued degeneration of the 
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remaining DA neurons.  The second paradigm consisted in reducing the overactivity of the 
subthalamic nucleus (STN), an excessively active output nuclei of the motor loop in PD, in order 
to restore a normalized output to the cortex.  A rAAV2 vector expressing glutamic acid 
decarboxylase, the enzyme that converts glutamate, an excitatory neurotransmitter into the 
inhibitory neurotransmitter GABA was injected in the STN.  A Phase I clinical trial demonstrated 
the safety and tolerability of rAAV2 injections into the STN.  Furthermore, 10 of 12 patients 
treated showed clinical improvements at 12 months (233,234).  
These therapeutic strategies are however only compensatory and are not expected to 
interfere with DA neuron cell death.  Providing neurotrophic support might constitute the first 
disease-interfering approach for PD.  A rAAV2 vector expressing Neurturin (NTN) has been 
evaluated in a Phase II clinical trial (235).  The virus was injected in the putamen.  At 12 months 
post-surgery, no statistical improvement in the main clinical parameters could be established.  
However, in a subset of patients reaching 18 months post-surgery, several parameters were 
significantly improved.  For 2 patients who died for unrelated causes, post-mortem analysis 
revealed that NTN covered approximately 15% of the putamen (236).  Contrary to data obtained 
with similar amounts of virus in monkey, though, very few NTN-positive cells were detected in 
the SN, suggesting a poor retrograde transport of NTN in patients.  A second clinical trial has 
been launched using both putamen and SN as delivery area.  However, several preclinical 
studies (237-239) and one clinical using GDNF (a NTN analog) recombinant protein (240) have 
described adverse effects related to uncontrolled dosage and off-target delivery of GDNF.  In 
order to address these safety issues, e.g. in the case of neuroprotective strategies, it will be 
necessary to regulate transgene expression in order to adapt the dose of the transgene product 
to the patients needs or even interrupt the treatment.  The on-going development of rAAV 
vectors with enhanced targeting and better genetic regulation also could provide a opportunity 
to deliver and express GDNF in a more controlled manner. 
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Correction of lysosomal enzyme deficiencies has also generated promising preclinical 
data.  This has been demonstrated in rAAV-mediated gene transfer for mucopolysaccharidosis 
type III (MPSIII) a disorder caused by the absence of one of the lysosomal enzymes required for 
the degradation of heparan sulfate (HS) resulting in the accumulation of heparan sulfate 
oligosaccharides (HSOs).  In particular, in MPSIIIB, alpha-N-acetylglucosaminidase (NaGlu) 
deficiency is responsible for progressive mental neurodegeneration.  Intracerebral stereotactic 
injections of AAV5 vectors coding for the missing enzyme reversed alterations of HS 
degradation, corrected pathology in neuronal cells and prevented neuroinflammation at the 
organ level in animal models (241).  Recently, a clinical trial using a rAAVrh10 vector has been 
launched for MPSIIIA, a deficiency in heparan-N-sulfamidase (242). 
 
Muscular Diseases 
Some of the earliest studies in animal models established the potential of rAAV vectors 
for long-term muscle-directed gene transfer (243). This discovery led to intense efforts to use 
rAAV to treat devastating illnesses such as limb girdle muscular dystrophy 2D (LGMD2D), 
Duchenne muscular dystrophy (DMD), Pompe disease, as well as cardiovascular diseases.  
Two clear obstacles exist for using rAAV vectors to treat LGMD2D and DMD: the genes far 
exceed the packaging size 4.7kb limit of rAAV; and the doses required for systemic 
administration of skeletal muscle are incredibly high.  To overcome transgene restriction mini 
and micro-forms of the transgene and exon-skipping vectors have been engineered.  Due to the 
impracticality and safety of infusing patients with very large doses of vector, the clinical trials 
have usually focused on critical muscle areas in hopes of improving lifespan or quality of life.  In 
2006 a Phase I clinical trial was initiated for the treatment of DMD at the Nationwide Children’s 
Hospital in Columbus, Ohio (244).  Six boys with frame-shift mutations were treated with 
rAAV2.5 vectors carrying a functional mini-dystrophin transgene.  Three of the patients received 
a dose of 2.0×1010 vector genomes per kilogram body weight (VG/kg) and the three others were 
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administered 1.0×1011 VG/kg.  There were some mild adverse events described that included 
nausea or upset stomach, macular rash, fungal rash, and sore throat, but no moderate or 
severe adverse events were reported.  A dystrophin-specific T-cell response was observed and 
two of the patients had detectable levels of spontaneously primed T cells before treatment, 
indicating that these patients had developed self-reactive T cells during the course of their 
disease.  The authors of this study suggest that cellular immune responses should be examined 
during gene therapy trials for DMD.  One possible means to circumvent the immunotoxicity is by 
isolated limb perfusion.  It has been shown that the selective regional administration of rAAV 
vectors to limbs of mice, dogs, and non-human primates allows for substantial transduction with 
decreased immune activation (245-247). 
 
Diseases of the Eye 
One of the most promising target tissues for gene delivery using rAAV vectors is the eye. 
Due the lower doses required and the fact that the eye is relatively immune privileged, some 
notable trials have demonstrated success.  In particular the treatment of Leber’s congenital 
amaurosis (LCA) and the wet form of macular degeneration have provided evident safety 
profiles and exciting clinical results.  All of these trials have used subretinal injection and vectors 
based on the AAV2 serotype to deliver the therapeutic genes, due to the propensity for this 
platform to efficiently target the retina (248,249). 
LCA is the most common and severe form of inherited childhood blindness and is 
caused by severe retinal degeneration of the photoreceptor cells or the retinal pigment 
epithelium (250).  A number of different genes have been shown to be involved in this 
dystrophy, with mutations in the retinal pigment epithelium-specific 65-kDa protein (RPE65) 
gene causing disease in approximately 6% of the patients (251).  The RPE65 gene codes for an 
enzyme that is responsible for the isomerohydrolase activity in the retinal pigment epithelium.  
Studies in animal models showed that rAAV2-RPE65 gene delivery could safely replace 
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functional protein for more than 7 years, establishing a clear rationale for human therapy (252).  
In 2008, three reports were published from independent early-phase clinical trials that explored 
the gene delivery of RPE65 in young LCA patients (128,130,253).  A total of nine subjects 
between the ages of 17 and 26 were treated in these early studies, with vector administration in 
one eye and the contralateral eye as a control.  While retinal complications did occur in two of 
the patients, these were likely related to the surgical procedure and no serious adverse events 
were reported.  Furthermore, there was no evidence for systemic toxicity or immunogenicity to 
the vector.  Despite the differences in transgene construction, dose delivered, and retinal 
degeneration in the patients, there was evidence for visual improvement in each trial.  A 
substantial deficiency in low-light vision is a hallmark deficiency in LCA; seven of the nine 
patients reported improved vision in dim light environments.  Subsequent reports, which 
included vector re-administration in 3 patients, have continued to demonstrate the long-term 
efficacy of rAAV2-RPE65 gene delivery, without safety difficulties or the induction of cytotoxic T-
cells against the vector or transgene (254-256).   
AAV is also being evaluated in two separate clinical trials that are delivering the soluble 
vascular endothelial growth factor (VEGF) Flt-1 (sFlt-1) gene to block neo-vascularization of the 
eye in the “wet” form of age-related macular degeneration (AMD), a leading cause of vision loss 
in the elderly (257).  Preclinical data performed in mice, rats, and monkeys in support of these 
studies has demonstrated that the treatment is capable of long-term expression and well 
tolerated (258,259).  Early reports from the trial led by Rakoczy et al. indicate that no signs of 
inflammation or increase in T-cell activation, even though patients with preexisting neutralizing 
antibodies to AAV2 were not excluded from the study (260).  While transgene sequences were 
detected in the tear samples from two of the subjects the day after dosing, this vector shedding 
was transient.  In addition, evidence of efficacy was also reported, since the most of the patients 
had improved vision and were able to discontinue the standard injections of the monoclonal 
antibody fragment, ranibizumab. 
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Together these findings suggest that AAV-mediated gene delivery is a safe and effective 
means to treat ocular diseases and has created renewed enthusiasm in gene therapy.  The 
current route of delivery, however, has been through injection into the subretinal space, a 
procedure that may not be well tolerated in other disorders like retinitis pigmentosa in which the 
retina is weak.  Newer delivery methods and enhanced vectors are currently being developed 
that offer the capability to transduce numerous cell types in the retina though less invasive 
means such as intravitreal injections (261).   
 
Hemophilia B 
Hemophilia B is an X-linked bleeding disorder that is caused by the lack of blood 
coagulation Factor IX (FIX) in affected patients.  The current standard of care is prophylactic 
injections of recombinant or plasma-derived FIX on a weekly or twice-weekly basis to maintain 
low bleeding rates and on demand treatment to control a bleeding episode.  While this enables 
management of the disease, inhibitor development, the burden of regular injections, and the 
very high cost for the clotting factor infusions are problematic.  The treatment of hemophilia B 
using gene delivery has been considered promising for many years.  This is due to the fact that 
FIX is in the circulation and therefore can be expressed from multiple tissue types.  Another 
reason is that only a small portion of normal protein expression is needed for a therapeutic 
effect; hemophilia B can be treated with as little as 1% of normal circulating levels of Factor IX 
and levels above 5% are considered mild. 
The first trial was a dose-escalation study that used a rAAV2 vector to deliver FIX to 
skeletal muscle (262).  Importantly, the inclusion criteria included that the subjects have 
missense mutations and no history of FIX inhibitor development, and did not exclude patients 
with neutralizing AAV2 antibodies.  The dose range was 2×1011 to 1.8×1012 VG/kg and safety 
results were encouraging for all the doses: there was no indication of vector-related toxicity, 
increased humoral response, or dissemination to patient semen.  In addition, the persistence of 
30 
 
transgene sequence and modest FIX expression suggested that the treatment offered a low 
level of gene delivery, though circulating levels of FIX did not reach therapeutic levels (263).  
The second trial also used an AAV2-based vector, but in this study the administration was 
through the hepatic artery (264).  No acute or systemic toxicity was reported, but a short-lived 
rise in liver transaminases was observed.  The authors described a transient level of therapeutic 
levels of FIX with the highest vector dose and it was proposed that CD8-positive T-cell 
responses to the AAV2 capsid were the cause of vector clearance (265,266). 
In a more recent trial, a rAAV8 vector was used to deliver a codon optimized self-
complementary FIX transgene driven by a tissue-specific promoter to the liver of hemophilia B 
patients by intravenous injection, thereby utilizing the natural tropism of AAV8 for the liver (267).  
Vectors based on AAV8 are also thought to be less likely to induce an immune response, since 
the prevalence of neutralizing antibodies to AAV8 in the human population is relatively low and 
AAV8 does not utilize heparin sulfate for cellular attachment and therefore may not be 
presented on dendritic cells as readily (81,268).  No neutralizing antibodies or T-cell response to 
FIX were detected in any of the patients.  Humoral responses to AAV8 capsid were observed in 
all the subjects and varied AAV8-capsid specific T-cell responses that correlated with vector 
dose.  A significant rise in liver enzymes was seen in one of the six patients and correlated with 
a decrease in FIX expression, suggesting that a cytotoxic T-cell against transduced hepatocytes 
was the cause.  This immune response was treated with prednisolone without further 
complications.  Notably, the results of this trial indicated that gene delivery was very successful 
in treating the disease.  All patients developed circulating FIX levels of between 1% and 6% for 
more than 2 years and exhibited less dependence on FIX protein replacement treatments.  Four 
of the patients were able to stop taking prophylactic injections, while the two other subjects were 
able to reduce their number of infusions.  This trial has been seen as a critical milestone in 
rAAV-mediated gene delivery due to its clear efficacy and safety endpoints. 
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Storage Diseases 
Another area where treatment with rAAV vectors has demonstrated success is in the 
treatment of storage diseases.  Lipoprotein lipase (LPL) deficiency is a rare autosomal 
recessive disease mainly characterized by recurrent and potentially fatal pancreatitis (269).  LPL 
is the main enzyme in the catabolism of triglyceride (TG)-rich lipoproteins called chylomicrons.  
In LPL-deficient patients, impaired chylomicron clearance from the circulation leads to extremely 
elevated levels of serum triglycerides.  A natural gain-of-function variant, LPLS447X (270), has 
been used to generate alipogene tiparvovec (or Glybera), a rAAV1-LPLS447X vector that 
restored normal levels of chylomicrons in patients 12 weeks after intramuscular injection.  
However, at long-term, the plasma triglyceride levels, which were chosen as primary efficacy 
endpoint, returned to baseline (271).  It was first hypothesized that T-cells responses directed 
against AAV1 could be responsible for this apparent drop of vector activity (272), but it was 
afterwards realized that the triglyceride level was not an adequate primary endpoint to assess 
treatment efficacy.  Other characteristics of the TG-rich lipoproteins rather than plasma 
triglycerides content were better reflecting pancreatitis risk and were shown to be stably 
corrected.  In addition, despite the presence of anti-capsid antibodies, vector DNA and 
transgene expression persisted at least until 26 weeks and a strong tendency for reduced 
pancreatitis frequency during a 2-years follow-up in an open-label trial (273).  Apart from muscle 
pain due to the high number of muscle injections, no adverse effect was reported.  Interestingly, 
this clinical trial offered the possibility to study AAV integration profile in a large number of 
events in 5 LPL-deficient patients (444,433 reads from 25 muscle biopsies) (167).  The study, 
using LAM-PCR and deep sequencing revealed a largely random integration profile.  In contrast 
to other AAV integration studies, no preferential integration within genes has been observed.  
Only very few integration hotspots were found in the nuclear as well as (even more frequently) 
in mitochondrial DNA.  The integration frequency (10-4 to 10-5) is approximately one order of 
magnitude higher than in other studies but it is still much lower than that of retroviral vectors.  
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This is in striking contrast to the data obtained in very specific mice models involving partial 
hepatectomy in a cancer-prone model which raised the potential of AAV-mediated oncogene 
activation via insertional mutagenesis in particular in one locus, called AAV-HCC l (162).  In the 
AAV1-LPLS447X, no integration in the AAV-HCC locus was discovered. Interestingly, no 
accumulation in the AAVS1 locus, the wild-type AAV preferential integration site was observed. 
This clinical trial was also the first to establish the safety of clinical-grade AAV vectors 
manufactured with the bacullovirus technology that offers to possibility to produce larger scale 
batches than previously (273). 
Due to the restricted number of patients worldwide and to the initial difficulty to find a 
reliable output measure of efficacy, it has been difficult to statistically establish the benefit of the 
therapy.  Therefore, despite the very extensive and convincing data regarding safety (minimal 
shedding, limited and transient elevation of anti-capsid antibodies and no cellular immune 
response; see table1), the EMA repeatedly rejected the application for market authorization due 
to an estimated low benefit in balance with the expected discomfort of the high number of 
injections and risks related to the transient immune-suppression in the protocol.  However, when 
postprandial chylomicrons clearance and triglyceride content of the chylomicron lipoprotein 
fraction was taken as the efficacy endpoint, a prolonged effect of the gene therapy with levels in 
treated patients similar to those of normal subjects has been demonstrated (273).  Glybera has 
finally been accepted as the first commercialized gene therapy product in the Western world in 
November 2012 (274,275). 
Importantly, as required by Directives 2001/83/EC and 726/2004 from the European 
Parliament and the Council of the European Union, a thorough environmental risk assessment 
was performed for Glybera (281).  This biosafety review evaluated the risks associated with 
vector dissemination through shedding, germ line transfer, and mobilization, wild-type AAV 
contamination, non-specific integration, and other biosafety possibilities.  The study concluded 
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that the vector poses only a negligible risk to the environment, including healthcare workers, 
friends and family, pets, or others that come in contact with Glybera treated individuals.   
 
Future 
AAV-based vectors have an impressive safety record and this has advanced their use to 
more laboratories and clinical trials.  The approval of Glybera illustrates the potential for rAAV 
vectors and will possibly be the first of many.  For the widespread use of rAAV vectors to 
become a reality, it will be necessary to overcome the current challenges of efficacy and safety.  
These include decreasing the immunogenicity of AAV-based therapies, and limiting the non-
specific integration, off-target effects of transgene expression.   
While not directly related to safety of the vector, it is now becoming clear that immune 
activation by rAAV vectors is the major challenge that will need to be overcome to fulfill the 
promise of AAV-mediated gene therapy (276-278).  Unlike Ad vectors, rAAV vectors have not 
been associated with a high risk of tissue and organ inflammation, but both innate and adaptive 
immune responses are known to limit rAAV vector transduction and eliminate transduced cells.  
In the future it will be important to identify the best means to decrease the immune activation to 
the vector and the transgene product.  This path will likely involve developing vectors with better 
immune evasion, the limited use of immunosuppression, and controlling vector production to 
create higher purity drug products.   
 
Concluding Remarks 
Every form of new and important therapy has come with inherent risks.  Blood 
transfusion, for example, was once a risky and controversial procedure (279).  In the past 100 
years the scientific community has worked diligently to overcome the problems of immune 
rejection and infections that have complicated the procedure.  Likewise, gene therapy will need 
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to address the pitfalls that could limit the effectiveness of treatment or endanger patient health.  
For rAAV vectors, many of the hurdles have been identified and work is currently underway to 
enhance further its safety and efficacy which now has accumulated from this platform vector 
that has now been tested in brain, eye, heart, lung, liver and muscle with minimum risk.  As 
these improvements are made there will be benefits for basic scientists as well as for patients.  
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Figure Legends 
 
Figure 1.  Organizational structure of AAV genome.  The genome of AAV is divided into two 
main gene segments, rep and cap.  The two larger rep transcripts (rep78 and rep68) are 
produced from the p5 promoter.  The full-length transcript is rep78, while alternative splicing is 
used to generate rep68.  The two smaller rep sequences are coded from the p19 promoter, and 
produce rep52 and an alternatively spliced transcript, rep40.  The three capsid subunits are 
coded by the cap gene from the p40 promoter, using a combination of alternative splicing and 
the unique ACG start codon for VP2.  A second open reading frame that is nested within cap is 
used for translation of AAP.  The Inverted Terminal Repeats (ITRs) that flank the viral genome 
are the only components conserved in rAAV vector transgenes. 
 
Figure 2.  AAV transduction pathway.  AAV or rAAV vectors can effectively transduce target 
cells in the absence of helper virus through the following steps: Receptor binding, Receptor-
mediated endocytosis, subcellular trafficking with endosomal compartments, activation of viral 
phospholipase and escape from the endosome, entry into the nucleus, capsid uncoating and 
genome release, second-strand synthesis, and persistence of the transgene as episomal DNA 
concatamers.   
 
Figure 3.  Tropism of natural AAV serotypes.  Preclinical and clinical data has confirmed that 
numerous AAV serotypes can effectively transduce a number of tissues including the brain, eye, 
lung, liver, skeletal muscle, and heart. 
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Table 1. 
 
 
Table	1:	Summary	of	the	lessons	from	clinical	trials	regarding	the	biosafety	of	rAAV	vectors	
	
	 Mode	of	
administration	
Disease/vector	 Conclusion	 References	
Shedding	and	
biodistribution	
	 	 	 	
	 Intra-muscular	
quadriceps	(40-60	
injections)	
LPL	deficiency/AAV1-LPLS447X	 Shedding	(i.e.	the	dissemination	in	any	form	into	the	environment	via	
excreta	(urine,	feces,	sweat,	saliva,	nasopharyngeal	fluids)	:	At	24H.	
serum,	saliva,	urine.	undetectable	after	4-6	weeks	except	in	one	
subject.			
Presence	of	viral	sequences	in	semen	:	low	levels	at	one	week,	
clearance	between	6-10	weeks.	
(273)	
	 subretinal	 Leber	congenital	amaurosis	
type	2	(LCA2)/AAV2.hRPE65	
Transient	positivity	in	serum	and	tears	 (280)	
Integration	 	 	 	 	
	 Intra-muscular	
quadriceps	
(40-60	injections)	
LPL	deficiency/AAV1-LPLS447X	 Largely	random	 (167)	
Immune	response	 	 	 	 	
	 Intra-muscular	
quadriceps	
(40-60	injections)	
LPL	deficiency/	AAV1-LPLS447X	 Anti-capsid	antibodies	not	associated	with	a	drop	of	transgene	
expression.	
No	anti-	LPLS447X	antibodies	
(273)	(272)		
	 Intra-hepatic	artery	 Hemophilia	B/	AAV2-FIX	
	
	
Hemophilia	B/scAAV8-FIX	
Liver	specific	promoter/codon	
optimized-FIX	
CD8-positive	T-cell	responses	to	the	AAV2	capsid/	vector	clearance	in	
the	high-dose	cohort.	
	
Therapeutically-relevant	FIX	levels	reached	in	the	high-dose	cohort.	
Transient	rise	in	liver	transaminases	accompanied	by	a	raise	in	anti-
capsids	T	cells	treated	by	transient	glucocorticoïd	treatment.	
Maintenance	of	transgene	expression.	
(265)	
	
	
(267)	
	 subretinal	 RPE/AAV2.hRPE65	 No	neutralizing	antibodies,	except	transiently	in	one	subject.		
No	anti-transgene	antibodies.	No	cellular	immune	response.		
No	rejection	of	transduced	cells	after	re-administration	in	contralateral	
eye	in	3	patients.	
(256)	(280)	
	
Note	:	This	table	reviews	only	data	from	clinical	trials.	The	numerous	preclinical	data	available	are	not	thoroughly	described	in	the	present	review.	An	extensive	
review	covering	pre-clinical	and	clinical	data	on	the	shedding	of	rAAV2	depending	on	the	route	of	administration	until	2010	has	been	provided	by	Brandon	and	
colleagues	(133).	
